SpringWorks Therapeutics IncSpringWorks Therapeutics Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

This ESG rating for SpringWorks Therapeutics Inc indicates its reporting of the United Nations Sustainable Development Goals. The ESG score includes 17 UN Sustainable Development Goals including: 'Good Health & Wellbeing', 'Industry, Innovation & Infrastructure' and 'Partnerships for the Goals'. If you are employed by SpringWorks Therapeutics Inc and you would like to licence your Sustainability aseessment, please contact us.

SpringWorks Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.9; made up of an environmental score of 1.3, social score of 3.4 and governance score of 4.0.

SDG Transparency Score for SpringWorks Therapeutics Inc 

2.9

Low Impact
0 - 3
Medium
4 - 6
High
7 - 10
Last Score Update: 2024-05-01
What drives the score for SpringWorks Therapeutics Inc 
1.3

Environmental

3.4

Social

4.0

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Caladrius Biosciences Inc
8.0
High
1Can Fite Biopharma Ltd
8.0
High
.........
1336SyneuRx International (Taiwan) Corp
3.0
Medium
1336Sensorion SA
3.0
Medium
1353SpringWorks Therapeutics Inc
2.9
Medium
1353Caribou Biosciences Inc
2.9
Medium
1353Checkmate Pharmaceuticals Inc
2.9
Medium
.........
1970Zyden Gentec Ltd
0.0
Low
1970iNtRON Biotechnology Inc
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does SpringWorks Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc report the average age of the workforce?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc offer flexible work?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc conduct supply chain audits?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc disclose water use targets?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did SpringWorks Therapeutics Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has SpringWorks Therapeutics Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is SpringWorks Therapeutics Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc disclose its waste policy?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc disclose energy use targets?

LockedSign up for free to unlock

Does SpringWorks Therapeutics Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does SpringWorks Therapeutics Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for SpringWorks Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

Sorry!

Failed to process!